Research Article
The Utility of 18F-FDG PET/CT for Monitoring Response and Predicting Prognosis after Glucocorticoids Therapy for Sarcoidosis
Table 2
Patient data, ROIs, and
.
| | Patient | Age (y) | sex | Intrathoracic involvement | Number of ROIs | | Metabolic response | Recurrence
time (m) | | Baseline | 1 month | 2 months | 3 months |
| | (1) | 37 | M | II | 4 | 23.8 () | 11.9 () | 0.0 () | | CMR | - | | (2) | 61 | F | II | 1 | 11.1 | 4.8 | | | PMR | - | | (3) | 62 | F | II | 2 | 18.5 () | 5.4 () | | | PMR | 55 | | (4) | 66 | F | II | 3 | 30.4 () | | 21.1 () | | PMR | 9 | | (5) | 60 | M | I | 1 | 7.8 | 0 | | | CMR | - | | (6) | 39 | M | I | 1 | 7 | | 0 | | CMR | - | | (7) | 46 | F | IV | 5 | 31.6 () | 22.3 () | 15.3 () | | PMR | 10 | | (8) | 52 | F | II | 4 | 24.7 () | | 20.1 () | | SMD | 44 | | (9) | 55 | M | I | 3 | 20.0 () | 10.1 () | 0.0 () | | CMR | - | | (10) | 64 | M | I | 1 | 8.1 | | 0 | | CMR | - | | (11) | 67 | F | I | 1 | 20.9 | 13.3 | 5.1 | 0 | PMR | - | | (12) | 62 | F | II | 3 | 22.3 () | | | 17.8 () | SMD | 6 | | (13) | 25 | F | I | 3 | 19.8 () | 15.5 () | | 13.9 () | PMR | 8 | | (14) | 61 | M | IV | 1 | 7.1 | | 5.7 | | SMD | 11 | | (15) | 70 | F | I | 4 | 20.8 () | | 3.1 () | | CMR | - | | (16) | 47 | F | I | 7 | 20.2 () | | | 15.6 () | SMD | 9 | | (17) | 46 | F | I | 1 | 19.9 | | | 21.1 | SMD | 10 | | (18) | 47 | F | I | 3 | 17.5 () | | | 8.3 () | PMR | - | | (19) | 32 | M | I | 4 | 27.1 () | | 22.3 () | | SMD | 6 | | (20) | 58 | F | IV | 2 | 14.3 () | | 13.4 () | | SMD | - | | (21) | 48 | M | II | 4 | 22.5 () | 18.4 () | | 9.6 () | SMD | 13 | | (22) | 18 | M | I | 3 | 17.7 () | 14.6 () | | | SMD | - | | (23) | 41 | M | I | 5 | 13.6 () | 11.1 () | | | SMD | 11 |
|
|
